TrialJournal of diabetes investigation2024

Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.

Daisuke Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.